Partnership brings together proven non-cryogenic biosample preservation technology and advanced organoid models to support growth in preclinical research and biotech sectors
Newcastle, UK, 15th 十二月 2025: Atelerix, a biotech company revolutionising cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced it has entered a partnership with Cherry Biotech, a French company specialising in organ-on-chip and organoid technologies for biomedical research.
The initial agreement will explore the integration of Atelerix’s patented hydrogel technology with Cherry Biotech’s advanced 3D organoid models to facilitate global extended-duration shipment. In collaboration, the companies aim to improve the reliability and consistency of transporting these temperature-sensitive materials without the complications of cold-chain logistics, enabling significant growth and expanded customer access to high-quality, human-relevant preclinical data worldwide. Through an initial 12-month trial period, both parties will validate their strategic and technical alignment, establishing the groundwork for a scalable, long-term commercial partnership.
Cherry Biotech’s in vitro product range combine AI analysis, high-resolution live imaging and precisely controlled organoid culture to better predict the efficacy and safety of drugs, generating real life-like preclinical data. As part of the partnership, Atelerix’s hydrogel technology will also be validated for the stable shipment of Cherry Biotech’s recently released organoidPlate – an advanced multiwell plate with ready-to-use organoids for adipose tissue, breast cancer, liver and lung, which is now available for worldwide shipping.
The MoU builds on a test period whereby Cherry Biotech demonstrated strong performance of Atelerix’s biosample preservation technology across multiple organ models, preserving membrane integrity and biological function at ambient or controlled temperatures.
Alastair Carrington, CEO, Atelerix, commented: “This latest partnership with Cherry Biotech is a key step in expanding our commercial traction, broadening market reach, and increasing visibility for Atelerix’s solutions. It is fantastic to work alongside such an innovative CRO, we are delighted that our preservation technology has already proven itself in delivering organoid models reliably and hassle-free to researchers worldwide. This partnership provides key validation, reinforcing the potential of ambient logistics to support the adoption of assay-ready animal model alternatives, advancing drug testing and better predicting human responses.”
Pierre Gaudriault, Chief Business Development Officer, Cherry Biotech, added: “Partnering with Atelerix strengthens our ability to deliver cutting-edge organoid models to researchers in pharma and academia worldwide. The hydrogel preservation technology maintains cell viability for days at room temperature, removing cold-chain constraints and reducing environmental footprint. This innovation brings unprecedented convenience and reliability to our customers. In short, Aterelix is making easy global shipping for our product possible”
完
编辑须知：
 |  |  |
| Alastair Carrington, CEO, Atelerix | Pierre Gaudriault, Chief Business Development Officer, Cherry Biotech | Cherry Biotech’s 3D Human Mature Adipose Tissue Organoid from an AdipoPlate |
如需高分辨率图片，请联系Zyme Communications。
如需了解更多信息，请联系：
阿拉斯泰尔·卡灵顿
Atelerix
电子邮件：alastair.carrington@atelerix.co.uk
Zyme Communications
杰克·布朗
Zyme Communications
电话：+44(0) 7759 162 147
电子邮件：jake.brown@zymecommunications.com
如需取消订阅 Zyme Communications 的新闻稿，请发送电子邮件至 info@zymecommunications.com。如需查看我们的隐私政策，请 点击此处。
关于 Atelerix www.atelerix.co.uk
Atelerix 凭借其低温保存技术，正在开创一种独特的生物样本非冷冻储存和运输方案。
Atelerix 的水凝胶解决方案源自海藻，并从非洲四趾侏儒刺猬的冬眠机制中汲取灵感，从而消除了对昂贵且耗能的冷链供应的需求。这些水凝胶旨在通过物理封装技术包裹细胞并维持脂质膜的完整性，从而使细胞、组织和病毒能在室温下稳定保存长达两周。
如需了解更多信息，请访问www.atelerix.co.uk，并在LinkedIn 上关注我们。
About Cherry Biotech www.cherrybiotech.com
Cherry Biotech is a French company that develops products and expertise in complex 3D cell culture, like organoids or organ on chip. The product portfolio of Cherry Biotech aimed at helping researchers in pharma, academia and CRO to generate real life like preclinical data during for drug discovery and personalised medicine. Its mission is to replace animal wherever possible by providing human physiology mimicking in vitro models..
Among its noticeable products, the OrganoidPlate provide its user with a standard multiwell plate loaded with ready to use mature and differentiated organoids. Saving up to 3 weeks in culture time, allowing the user to focus on the data generation.
In addition, Cherry Biotech’s CUBIX platform enables pharmaceutical, biotech companies and healthcare providers to recreate immunocompetent human vascularized organ models and tumor microenvironments for better evaluation of their drug candidates.
By enabling the reconstruction of human 3D models that mimic human physiology and pathophysiology over several weeks, Cherry Biotech’s proprietary CUBIX technology is the only solution that can convert a standard 2D multi-well plate into a 3D cell culture (Organ on Well).
To learn more: www.cherrybiotech.com/
